公开(公告)号：US20150284430A1

公开(公告)日：2015-10-08

申请号：US14742656

申请日：2015-06-17

Applicant: Yun Cheng ,  Ruihe Yu

Inventor： YUN CHENG ,  Ruihe Yu ,  Hong Li ,  Wanzhou Zhao

IPC: C07K7/06

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08

Abstract: The present invention provides an application of an SP peptide or a derivative thereof in preparing medicines for preventing or treating asthma. The peptide or the derivative thereof is the SP peptide shown in Formula I or a pharmaceutically acceptable salt or ester thereof. The present invention also provides a method for treating asthma, the method comprises: administering to a patient with medicine containing the peptide or the derivative thereof with an effective therapeutic dosage. It proves through researches of the present invention that, the peptide or the derivative thereof can effectively alleviate pathological symptoms of asthma, especially pathological symptoms of allergic asthma. In the formula (I), Xaa1 is deletion, Ala, Gly, Val, Leu or Ile; Xaa2 is Thr or Ser; Xaa3 is Tyr, Phe or Trp; and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4  (Formula I)

Abstract translation: 本发明提供SP肽或其衍生物在制备用于预防或治疗哮喘的药物中的应用。 肽或其衍生物是式I所示的SP肽或其药学上可接受的盐或酯。 本发明还提供了一种治疗哮喘的方法，所述方法包括：以有效的治疗剂量向含有所述肽或其衍生物的药物给予患者。 通过本发明的研究证明，肽或其衍生物可以有效缓解哮喘的病理症状，特别是过敏性哮喘的病理症状。 在式（I）中，Xaa1是缺失型，Ala，Gly，Val，Leu或Ile; Xaa2是Thr或Ser; Xaa3是Tyr，Phe或Trp; 并且Xaa4是缺失型，Ala，Gly，Val，Leu，Ile或Pro。 Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4（式I）

公开(公告)号：US09605023B2

公开(公告)日：2017-03-28

申请号：US14742656

申请日：2015-06-17

Applicant: Yun Cheng ,  Ruihe Yu

Inventor： Yun Cheng ,  Ruihe Yu ,  Hong Li ,  Wanzhou Zhao

IPC: C07K7/06 ,  A61K38/08 ,  A61K38/00

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/08

Abstract: The present invention provides an application of an SP peptide or a derivative thereof in preparing medicines for preventing or treating asthma. The peptide or the derivative thereof is the SP peptide shown in Formula I or a pharmaceutically acceptable salt or ester thereof. The present invention also provides a method for treating asthma, the method comprises: administering to a patient with medicine containing the peptide or the derivative thereof with an effective therapeutic dosage. It proves through researches of the present invention that, the peptide or the derivative thereof can effectively alleviate pathological symptoms of asthma, especially pathological symptoms of allergic asthma. In the formula (I), Xaa1 is deletion, Ala, Gly, Val, Leu or Ile; Xaa2 is Thr or Ser; Xaa3 is Tyr, Phe or Trp; and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4  (Formula I)

公开(公告)号：US07985734B2

公开(公告)日：2011-07-26

申请号：US12066636

申请日：2006-06-01

Applicant: Yun Cheng ,  Ruihe Yu ,  Wan Zhou Zhao ,  Jun Zhao ,  Jing Li

Inventor： Yun Cheng ,  Ruihe Yu ,  Wan Zhou Zhao ,  Jun Zhao ,  Jing Li

IPC: A61K38/08

CPC classification number: A61K38/08

Abstract: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.

Abstract translation: Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4（式（I））表示具有式I或其衍生物的肽在制备用于预防或治疗肝损伤，特别是肝损伤和丙型肝炎的药物中的应用 I）其中Xaa1是缺失型，Ala，Gly，Val，Leu或Ile，Xaa2是Thr或Ser，Xaa3是Tyr，Phe或Trp，Xaa4是缺失，Ala，Gly，Val，Leu，Ile或Pro。 还公开了含有所述肽的复合药物及其制备方法和用于编码所述肽的多核苷酸。

公开(公告)号：US20140235545A1

公开(公告)日：2014-08-21

申请号：US14229686

申请日：2014-03-28

Applicant: YUN CHENG ,  RUIHE YU ,  WANZHOU ZHAO

Inventor： YUN CHENG ,  RUIHE YU ,  WANZHOU ZHAO

IPC: C07K7/06

CPC classification number: C07K7/06 ,  A61K38/08

Abstract: The present invention provides the use of hepatitis C virus immunogenic peptides or derivative thereof in the manufacture of a pharmaceutical for preventing or treating arthritis, wherein the peptide or derivative thereof is a peptide represented by formula I or pharmaceutically acceptable salt or ester thereof. The present invention further provides a method for treating arthritis, including administering a pharmaceutical containing therapeutically effective amount of said peptide or derivative thereof to a patient. Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I), wherein, Xaa1 is deleted, or Xaa1 is Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deleted, or Xaa4 is Ala, Gly, Val, Leu, Ile or Pro.

Abstract translation: 本发明提供丙型肝炎病毒免疫原性肽或其衍生物在制备用于预防或治疗关节炎的药物中的用途，其中所述肽或其衍生物是由式I表示的肽或其药学上可接受的盐或酯。 本发明还提供了一种治疗关节炎的方法，包括向患者施用含有治疗有效量的所述肽或其衍生物的药物。 Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4（式I），其中Xaa1缺失，或Xaa1是Ala，Gly，Val，Leu或Ile，Xaa2是Thr或Ser，Xaa3是Tyr，Phe 或Trp，Xaa4被缺失，或Xaa4是Ala，Gly，Val，Leu，Ile或Pro。

公开(公告)号：US08263562B2

公开(公告)日：2012-09-11

申请号：US13162981

申请日：2011-06-17

Applicant: Yun Cheng ,  Ruihe Yu ,  Wanzhou Zhao ,  Jun Zhao ,  Jing Li

Inventor： Yun Cheng ,  Ruihe Yu ,  Wanzhou Zhao ,  Jun Zhao ,  Jing Li

IPC: A61K38/08

CPC classification number: A61K38/08

Abstract: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.

Abstract translation: Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4（式（I））表示具有式I或其衍生物的肽在制备用于预防或治疗肝损伤，特别是肝损伤和丙型肝炎的药物中的应用 I）其中Xaa1是缺失型，Ala，Gly，Val，Leu或Ile，Xaa2是Thr或Ser，Xaa3是Tyr，Phe或Trp，Xaa4是缺失，Ala，Gly，Val，Leu，Ile或Pro。 还公开了含有所述肽的复合药物及其制备方法和用于编码所述肽的多核苷酸。